AICS

Onto Innovation Launches U.S. Applications Center of Excellence Focused on Panel-Level Packaging

Retrieved on: 
Monday, July 10, 2023
Technology, Hardware, Semiconductor, Surjective function, Onto Innovation, Original equipment manufacturer, Research, AICS, Interest, PLP, Virtual Reality Applications Center, Growth, AI, R, Glass, NYSE, AR, Video game, Printed circuit board

Onto Innovation Inc. (NYSE: ONTO) today announced the launch of an Applications Center of Excellence, a combined tool demonstrator, photo resist qualification, process integration and research and development (R&D) facility focused on panel-level packaging (PLP), a key facilitator of the emerging chiplet market.

Key Points: 
  • Onto Innovation Inc. (NYSE: ONTO) today announced the launch of an Applications Center of Excellence, a combined tool demonstrator, photo resist qualification, process integration and research and development (R&D) facility focused on panel-level packaging (PLP), a key facilitator of the emerging chiplet market.
  • The chiplet package market is expected to grow at an annual average rate of 103% over the next three years, according to TechSearch International.
  • With several significant industry inflection points on the horizon, such as glass substrate and increasingly tighter line/space requirements, the Applications Center of Excellence is ideally suited for advanced packaging process development for PLP, advanced IC substrates (AICS) and wafer-level packaging.
  • Interested customers and potential partner organizations should visit Onto Innovation during SEMICON® West at booth 629 or reach out to their local sales and support team to learn how to initiate collaboration at the Onto Applications Center of Excellence.

Soleo Health Selected as Sole Specialty Pharmacy Distributor of Newly FDA-Approved LEQEMBI™ (lecanemab-irmb) for Treatment of Alzheimer’s Disease

Retrieved on: 
Tuesday, January 10, 2023
Other Health, Radiology, Other Science, Software, Pharmaceutical, Research, Oncology, Medical Devices, Infectious Diseases, Hospitals, Technology, Fitness & Nutrition, Clinical Trials, Cardiology, Science, Biotechnology, Practice Management, Insurance, Nursing, Managed Care, Medical Supplies, AIDS, General Health, FDA, Health, Diabetes, Professional Services, Practitioner, Caregiver, Health, FDA, AD, TCMC, Hope, Partnership, Patient, Eisai, Food and Drug Administration, MCI, AICS, Medicine, Hospital

Soleo Health , an innovative leader and national provider of complex specialty pharmacy services, announced today it has been selected by Eisai Inc., a developer of pharmaceuticals, as the sole specialty pharmacy distribution partner for newly U.S. Food & Drug Administration (FDA)-approved LEQEMBI™ (lecanemab-irmb) for the treatment of Alzheimer’s Disease (AD).

Key Points: 
  • Soleo Health , an innovative leader and national provider of complex specialty pharmacy services, announced today it has been selected by Eisai Inc., a developer of pharmaceuticals, as the sole specialty pharmacy distribution partner for newly U.S. Food & Drug Administration (FDA)-approved LEQEMBI™ (lecanemab-irmb) for the treatment of Alzheimer’s Disease (AD).
  • Soleo Health’s distinctive Alzheimer’s Disease TCMC is supported through the Company’s specialty pharmacy locations nationwide with pharmacy licensure in all 50 states.
  • “The selection of Soleo Health as the sole specialty pharmacy distributor for LEQEMBI reflects confidence in our clinical expertise and differentiated patient care model supporting patients in the neurology space.
  • For more information about LEQEMBI therapy and services through Soleo Health, contact the Company’s Alzheimer’s Disease TCMC at 844.960.9090 or via email at [email protected] .

Medigus: Eventer Technologies Signed a Definitive Agreement for Reverse Merger to Become a Public Company

Retrieved on: 
Monday, January 9, 2023
Tel Aviv Stock Exchange, MDGS, NIS, Eventing, Agreement, Marketing, AICS, TASE, Security (finance)

Tel Aviv, Israel, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies, and electric vehicle and charging solutions, announced today that its 46.21% owned subsidiary, Eventer Technologies Ltd. ("Eventer"), a software company engaged in the development of platforms enabling producers and venues to create virtual conferences and events including a smart ticketing solution, signed a definitive agreement ("Agreement") for a planned securities exchange with AI Conversation Systems Ltd. (TASE: AICS) ("AI Conversation Systems"), an Israeli company traded on the Tel-Aviv Stock Exchange.

Key Points: 
  • According to the Agreement, Eventer will become a wholly owned subsidiary of AI Conversation Systems, and in exchange, Eventer shareholders will receive 74.99% of the issued and outstanding share capital of AI Conversation Systems.
  • "We are thrilled to announce that Eventer, a subsidiary of Medigus, will become a public company on the Tel-Aviv Stock Exchange.
  • The transaction will only be completed if Eventer is valued at a minimum of $5.7 million (NIS 20 million), as determined by an independent appraiser.
  • Eventer has an exclusive license to use the Screenz.live platform that offers high-quality video conferencing for thousands of participants.

Medigus: Eventer Technologies Signed a Letter of Intent for Spin-Off and an approx. $13 million Reverse Merger

Retrieved on: 
Wednesday, November 16, 2022
Marketing, MDGS, Digital, Eventing, AICS, LOI, Robotics, Tel Aviv Stock Exchange, TASE, Online shopping

Tel Aviv, Israel, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies, and electric vehicle and charging solutions, announced today that its 46.21% owned subsidiary, Eventer Technologies Ltd. ("Eventer"), software company engaged in the development of platforms enabling producers and venues to create virtual conferences and events including a smart ticketing solution, signed a non-binding letter of intent ("LOI") for a planned securities exchange agreement with AI Conversation Systems Ltd. (TASE: AICS) ("AI Conversation Systems"), an Israeli company traded on the Tel- Aviv Stock Exchange.

Key Points: 
  • According to the LOI, the transaction will only be completed if Eventer is valued at least $13 million, as determined by an independent appraiser.
  • As a public company, Eventer is expected to have improved access to capital which should enable it to expand operations and activities in Israel and new markets internationally.
  • Eventer has an exclusive license to use the Screenz.live platform that offers high-quality video conferencing for thousands of participants.
  • The Companys affiliates in digital commerce include Gix Internet Ltd., Jeffs' Brands Ltd. and Eventer Technologies Ltd.

Virtis Health Unveils Infusion Centers in Birmingham and Mobile, Alabama

Retrieved on: 
Wednesday, October 12, 2022
Stem Cells, Practice Management, Nursing, Medical Supplies, Managed Care, LGBTQ+, FDA, Diabetes, Radiology, Pharmaceutical, Oncology, Medical Devices, Infectious Diseases, Hospitals, Genetics, Women, Fitness & Nutrition, Seniors, Teens, Cardiology, Men, Parenting, Children, AIDS, Family, Health, Surgery, Consumer, Baby Boomers, LinkedIn, Physician, Medicaid, Master of Science in Nursing, ICU, Rheumatoid arthritis, Population, Multiple sclerosis, Family, Health, Patient, Hospital Insurance and Diagnostic Services Act, MPH, Twitter, AICS, Facebook, Myasthenia gravis, University, Company, Medicare, AIC, Practice management, Immunodeficiency, Ulcerative colitis, Graves' ophthalmopathy, Suite, Degenerative disease, Public health, Medicine, Pharmaceutical industry, Hospital, Nursing, Science

Virtis Health is a division of Soleo Health , a national provider of complex specialty pharmacy services administered in the home or at alternate sites of care.

Key Points: 
  • Virtis Health is a division of Soleo Health , a national provider of complex specialty pharmacy services administered in the home or at alternate sites of care.
  • Both Virtis Health Birmingham and Virtis Health Mobile offer a range of therapy management services and treatments for patients with autoimmune disorders, including chronic inflammatory demyelinating polyneuropathy, multiple sclerosis and myasthenia gravis.
  • The Virtis Health Birmingham AIC is at 2100 Riverchase Center, Suite 310, in Hoover, AL, 35244, phone: 659-910-7260.
  • Virtis Health Birmingham named Jeffrey Burkett, MPH, FNP-C, CRNP, nurse practitioner, overseeing day-to-day operations and supervising the clinical practice.

Virtis Health Unveils Infusion Center in Atlanta

Retrieved on: 
Monday, October 10, 2022
Infectious Diseases, Hospitals, Health Insurance, Practice Management, Other Health, Managed Care, Health, Pharmaceutical, General Health, Physician, BSN, LinkedIn, Medicaid, ICU, Rheumatoid arthritis, Multiple sclerosis, Health, Patient, Hospital Insurance and Diagnostic Services Act, Twitter, AICS, RN, Facebook, Myasthenia gravis, FNP, Company, Medicare, AIC, Practice management, Ulcerative colitis, Immunodeficiency, Graves' ophthalmopathy, Suite, Degenerative disease, Medical device, Medicine

Virtis Health Atlanta is conveniently located at 1600 Oakbrook Drive, Suite 560B, Norcross, Ga., 30093, Phone: 678.325.1065.

Key Points: 
  • Virtis Health Atlanta is conveniently located at 1600 Oakbrook Drive, Suite 560B, Norcross, Ga., 30093, Phone: 678.325.1065.
  • Virtis Health Atlanta offers therapy management services and treatments for patients with autoimmune disorders, including chronic inflammatory demyelinating polyneuropathy, multiple sclerosis and myasthenia gravis.
  • Virtis Health Atlanta is open Monday Friday, 8:30 A.M. 5:00 P.M., with evenings and weekend appointments available upon request, and accepts a broad range of health insurance plans including Medicare and Medicaid.
  • Concurrent with the opening, Turquoise Holmes, FNP , was appointed nurse practitioner at Virtis Health Atlanta, supervising the overall clinical practice.

Soleo Health Adds AMVUTTRA™ (vutrisiran) to Its Specialty Pharmacy Portfolio

Retrieved on: 
Monday, October 3, 2022
Oncology, Research, Software, Medical Devices, Infectious Diseases, Hospitals, Genetics, Fitness & Nutrition, Science, Technology, Clinical Trials, Nursing, Cardiology, Medical Supplies, Biotechnology, FDA, Surgery, Diabetes, AIDS, Insurance, Health, Professional Services, Practice Management, Managed Care, Other Health, General Health, Radiology, Pharmaceutical, Solution, Pharmacist, Injection, Company, Pharmacy, Facebook, Joint Commission, LinkedIn, Twitter, FDA, AICS, Health, ACHC, Distinction, Practitioner, Amyloidosis, Polyneuropathy, Patient, Alnylam Pharmaceuticals, URAC, Medicine, Pharmaceutical industry

Soleo Health , an innovative leader and national provider of complex specialty pharmacy services, announced today it has added AMVUTTRA (vutrisiran) to its specialty pharmacy portfolio to treat adults with the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.

Key Points: 
  • Soleo Health , an innovative leader and national provider of complex specialty pharmacy services, announced today it has added AMVUTTRA (vutrisiran) to its specialty pharmacy portfolio to treat adults with the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
  • Soleo Health employs specially trained interdisciplinary teams comprised of highly experienced pharmacists, registered nurses, reimbursement specialists and patient care ambassadors each of whom is trained on the clinical profile and administration for AMVUTTRA.
  • This marks the fourth therapy Soleo Health now offers from Alnylam Pharmaceuticals rare disease product portfolio further strengthening our ability to care for more patients living with rare disease who benefit from innovative new therapies like AMVUTTRA, said Drew Walk, Soleo Health chief executive officer.
  • Frisco, Texas-based Soleo Health is an innovative national provider of complex specialty pharmacy services administered in the home or at alternate sites of care.

Virtis Health Expands Ohio Presence With Opening of Ambulatory Infusion Centers in Columbus and Cleveland

Retrieved on: 
Monday, September 12, 2022
Pharmaceutical, Oncology, Medical Devices, Infectious Diseases, Hospitals, Genetics, Fitness & Nutrition, Stem Cells, Practice Management, Nursing, Managed Care, Medical Supplies, Cardiology, Biotechnology, Diabetes, Surgery, AIDS, Health, Pica, Multiple sclerosis, Degenerative disease, Allergy, Suite, Medicare, MSN, Twitter, AICS, George Washington University, Bachelor of Science in Nursing, Graves' ophthalmopathy, Chamberlain University, Practice management, LinkedIn, Company, Rheumatoid arthritis, Health, Myasthenia gravis, Cincinnati, Critical care, Patient, University, Facebook, AIC, Medicaid, Family, Physician, Ulcerative colitis, Pediatrics, ICU, Nursing, Master of Science, APRN, Hospital Insurance and Diagnostic Services Act, Immunodeficiency, Doctor of Pharmacy, Medical device, Pharmaceutical industry, Medicine

Both Virtis Health Columbus and Virtis Health Cleveland offer a range of therapy management services and treatments for patients with autoimmune disorders, including chronic inflammatory demyelinating polyneuropathy, multiple sclerosis and myasthenia gravis.

Key Points: 
  • Both Virtis Health Columbus and Virtis Health Cleveland offer a range of therapy management services and treatments for patients with autoimmune disorders, including chronic inflammatory demyelinating polyneuropathy, multiple sclerosis and myasthenia gravis.
  • Virtis Health Columbus AIC is located at 6190 Shamrock Court, Suite 110, in Dublin, phone 614-339-3970.
  • Virtis Health Cleveland AIC is at 500 East Royalton Road, Suite 110, in Broadview Heights, phone 216-453-8570.
  • At Virtis Health Columbus, Katelyn Heilman, MSN, APRN, FNP-C, a board-certified family nurse practitioner, was named advanced nurse practitioner.

SMART Modular Technologies Launches its First Compute Express Link Memory Module

Retrieved on: 
Wednesday, August 31, 2022
Technology, Hardware, Data Management, ECC, Compute Express Link, DDR5, CXL, Engineering, FPGA, Original equipment manufacturer, DIMM, CPU, Memory, DRAM, XMM, ASIC, SMART, Multimedia, JEDEC, RAS, Poisoning, Ecosystem, SGH, Industry, AICS, Adoption, Video game console, Computer data storage

SMART Modular Technologies , Inc. (SMART), a division of SGH (Nasdaq: SGH ) and a global leader in memory solutions, solid-state drives, and hybrid storage products announces its new Compute Express Link (CXL) Memory Module, the XMM CXL memory module.

Key Points: 
  • SMART Modular Technologies , Inc. (SMART), a division of SGH (Nasdaq: SGH ) and a global leader in memory solutions, solid-state drives, and hybrid storage products announces its new Compute Express Link (CXL) Memory Module, the XMM CXL memory module.
  • View the full release here: https://www.businesswire.com/news/home/20220831005323/en/
    SMART Modular announces its first XMM CXL memory modules that help to boost server and data center performance.
  • (Graphic: Business Wire)
    The industry adoption of composable serial-attached memory architecture enables a whole new era for the memory module industry.
  • *The stylized S and SMART as well as SMART Modular Technologies and Compute Express Link (CXL) are trademarks and registered trademarks of SMART Modular Technologies, Inc. All other trademarks and registered trademarks are the properties of their respective owners.

Virtis Health Unveils Ambulatory Infusion Center in Houston

Retrieved on: 
Monday, August 29, 2022
Health, Hospitals, Practice Management, Other Health, Health Insurance, Managed Care, General Health, Medicaid, Texas Medical Center, Rheumatoid arthritis, Degenerative disease, Multiple sclerosis, Suite, AIC, Graves' ophthalmopathy, Physician, Health, APRN, LinkedIn, Practice management, Family, Medicare, Company, MSN, Twitter, Facebook, Immunodeficiency, Ulcerative colitis, AICS, Hospital Insurance and Diagnostic Services Act, Myasthenia gravis, Patient, Medical device, Medicine

Virtis Health , a national healthcare provider dedicated to therapeutic and diagnostic services for patients with complex conditions requiring specialty infusible and injectable medications, announced today its unveiling of an ambulatory infusion center (AIC) in Houston.

Key Points: 
  • Virtis Health , a national healthcare provider dedicated to therapeutic and diagnostic services for patients with complex conditions requiring specialty infusible and injectable medications, announced today its unveiling of an ambulatory infusion center (AIC) in Houston.
  • Virtis Health Houston is conveniently located at 6800 West Loop South, Suite 475, Bellaire, Texas 77041, in close proximity to Texas Medical Center.
  • Virtis Health Houston offers therapy management services and treatments for patients with autoimmune disorders, including chronic inflammatory demyelinating polyneuropathy, multiple sclerosis and myasthenia gravis.
  • Virtis Health Houston services patients in the metropolitan Houston area and surrounding communities, including Sugar Land, Spring, Katy, Kingwood, Stafford, Conroe and Texas City.